We are live on ! Find out more
KZIA

Kazia Therapeutics

23 hedge funds and large institutions have $13M invested in Kazia Therapeutics in 2026 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 7 increasing their positions, 4 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

75% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 4

17% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 6

5% more funds holding

Funds holding: 2223 (+1)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

24% less capital invested

Capital invested by funds: $17.1M → $13M (-$4.02M)

132.95% less ownership

Funds ownership: 148.42%15.47% (-133%)

Holders
23
Holders Change
+1
Holders Change %
+4.55%
% of All Funds
0.28%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.01%
New
7
Increased
7
Reduced
4
Closed
6
Calls
$7K
Puts
Net Calls
+$7K
Net Calls Change
+$7K
Name Holding Trade Value Shares
Change
Change in
Stake
BL
1
Bleichroeder LP
New York
$2.98M
SCM
2
Stonepine Capital Management
Oregon
$2.57M -$802K -115,180 -25%
Point72 Asset Management
3
Point72 Asset Management
Connecticut
$1.49M
Balyasny Asset Management
4
Balyasny Asset Management
Illinois
$1.44M +$1.34M +193,114 New
FLPIM
5
F.L. Putnam Investment Management
Massachusetts
$1.06M +$992K +142,469 New
VCIM
6
Velan Capital Investment Management
Georgia
$1.01M -$1.15M -164,685 -55%
DIG
7
Dauntless Investment Group
New Hampshire
$594K +$556K +79,831 +7,983,100%
SFA
8
Sequoia Financial Advisors
Ohio
$446K +$418K +60,000 New
WIM
9
Westside Investment Management
California
$375K +$136K +19,550 +63%
Royal Bank of Canada
10
Royal Bank of Canada
Ontario, Canada
$255K -$138K -19,793 -37%
Barclays
11
Barclays
United Kingdom
$179K
Raymond James Financial
12
Raymond James Financial
Florida
$117K +$110K +15,749 New
UBS Group
13
UBS Group
Switzerland
$104K +$95.7K +13,741 +7,120%
Rockefeller Capital Management
14
Rockefeller Capital Management
New York
$94.5K +$13.9K +2,000 +19%
LNWTC
15
Laird Norton Wetherby Trust Company
Washington
$92.3K +$86.3K +12,400 New
Qube Research & Technologies (QRT)
16
Qube Research & Technologies (QRT)
United Kingdom
$78.9K +$73.8K +10,608 New
FIA
17
FNY Investment Advisers
New York
$74K +$17.4K +2,500 +33%
Osaic Holdings
18
Osaic Holdings
Arizona
$65K +$60.8K +8,734 +87,340%
GI
19
GAMMA Investing
California
$11.7K +$9.3K +1,336 +576%
RhumbLine Advisers
20
RhumbLine Advisers
Massachusetts
$10.4K -$1.14K -163 -10%
BNP Paribas Financial Markets
21
BNP Paribas Financial Markets
France
$8.04K +$7.53K +1,081 New
Morgan Stanley
22
Morgan Stanley
New York
$7.44K
AF
23
Allworth Financial
California
$8
Alyeska Investment Group
24
Alyeska Investment Group
Illinois
-$5.09M -738,321 Closed
EAM
25
Empery Asset Management
New York
-$1.17M -170,000 Closed

KZIA Hedge Fund Activity: Q1 2026 in Review

23 of the 8,142 institutional investors tracked by Wall St. Rank reported a position in Kazia Therapeutics (KZIA) for Q1 2026, worth a combined $13M — down 24% from $17.1M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new KZIA positions and 6 closed out — a net gain of 1 holder — while 7 added to existing stakes and 4 trimmed.

The largest buyer was Balyasny Asset Management, opening a new position worth an estimated $1.34M. The largest seller was Alyeska Investment Group, exiting entirely with an estimated $5.09M sold.

  • 23 institutional investors held Kazia Therapeutics (KZIA) as of Q1 2026, up from 22 in Q4 2025.
  • Funds reported $13M of Kazia Therapeutics stock for Q1 2026, down 24% quarter-over-quarter.
  • 7 funds opened new Kazia Therapeutics positions in Q1 2026 and 6 closed out, a net change of +1 holder.
  • The largest Kazia Therapeutics buyer in Q1 2026 was Balyasny Asset Management, an estimated $1.34M added.
  • The largest Kazia Therapeutics seller in Q1 2026 was Alyeska Investment Group, an estimated $5.09M sold.

Based on aggregated 13F filings for Q1 2026.